Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease

National Science Review

Volumn 2, Issue 3, 2015, Pages 268-284

  Lei, Xiaobo ^a   Cui, Sheng ^a   Zhao, Zhendong ^a   Wang, Jianwei ^a,b  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antivirals; Enterovirus; Etiology; Foot and mouth disease; Hand; Innate immunity; Pathogenesis; Tropisms; Vaccine; Virus host interaction

Indexed keywords

EID: 84954142611     PISSN: 20955138     EISSN: 2053714X     Source Type: Journal    
DOI: 10.1093/nsr/nwv038     Document Type: Review

References (189)

1. Solomon, T, Lewthwaite, P and Perera, D et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778-90.
2. Xing, W, Liao, Q and Viboud, C et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 2014; 14: 308-18.
3. Huang, CC, Liu, CC and Chang, YC et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341: 936-42.
4. Robinson, CR, Doane, FW and Rhodes, AJ. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can Med Assoc J 1958; 79: 615-21.
5. Flewett, TH, Warin, RP and Clarke, SK. 'Hand, foot, and mouth disease' associated with Coxsackie A5 virus. J Clin Pathol 1963; 16: 53-5.
6. Duff, MF. Hand-foot-and-mouth syndrome in humans: coxackie A10 infections in New Zealand. Br Med J 1968; 2: 661-4.
7. Chumakov, M, Voroshilova, M and Shindarov, L et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 1979; 60: 329-40.
8. Nagy, G, Takátsy, S and Kukán, E et al. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 1982; 71: 217-27.
9. Ishimaru, Y, Nakano, S and Yamaoka, K et al. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child 1980; 55: 583-8.
10. Centers for Disease Control and Prevention (CDC). Deaths among children during an outbreak of hand, foot, and mouth disease-Taiwan, Republic of China, April-July 1998. MMWR Morb Mortal Wkly Rep 1998; 47: 629-32.
11. Ho, M, Chen, ER and Hsu, KH et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341: 929-35.
12. Chan, LG, Parashar, UD and Lye, MS et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000; 31: 678-83.
13. McMinn, P, Stratov, I and Nagarajan, L et al. Neurologicalmanifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001; 32: 236-42.
14. Chan, KP, Goh, KT and Chong, CY et al. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003; 9: 78-85.
15. AbuBakar, S, Sam, IC and Yusof, J et al. Enterovirus 71 outbreak, Brunei. Emerg Infect Dis 2009; 15: 79-82.
16. Khanh, TH, Sabanathan, S and Thanh, TT et al. Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg Infect Dis 2012; 18: 2002-5.
17. Wu, Y, Yeo, A and Phoon, MC et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010; 14: e1076-81.
18. China, HMoPsRo. Guidelines for Hand-foot-mouth disease prevention and control (2008). National Health and Family Planning Commission of the People's Republic of China, 2008.
19. Racaniello, VR. Picornarviridae: the viruses and their replication. In David, PMH and Knipe, M (eds). Fielda Virology, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2013.
20. Schmidt, NJ, Lennette, EH and Ho, HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129: 304-9.
21. Gilbert, GL, Dickson, KE and Waters, MJ et al. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 1988; 7: 484-8.
22. AbuBakar, S, Chee, HY and Al-Kobaisi, MF et al. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 1999; 61: 1-9.
23. Bendig, JW and Fleming, DM. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 1996; 6: R81-6.
24. Tu, PV, Thao, NT and Perera, D et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 2007; 13: 1733-41.
25. Mao, Q, Wang, Y and Yao, X et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 2014; 10: 360-7.
26. Yang, F, Ren, L and Xiong, Z et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 2009; 47: 2351-2.
27. Zhang, Y, Zhu, Z and Yang, W et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 2010; 7: 94.
28. McMinn, PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26: 91-107.
29. Liu, SL, Pan, H and Liu, P et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev Med Virol 2015; 25: 115-28.
30. Lukashev, AN. Recombination among picornaviruses. RevMed Virol 2010; 20: 327-37.
31. Chan, YF and AbuBaker, S. Recombinant human enterovirus 71 in hand, foot and mouth disease patients. Emerg Infect Dis 2004; 10: 1468-70.
32. Zhao, K, Han, X and Wang, G et al. Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis 2011; 17: 1537-40.
33. Mao, Q, Wang, Y and Yao, X et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 2014; 10: 360-7.
34. Hu, YF, Yang, F and Du, J et al. Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. J Clin Microbiol 2011; 49: 2426-34.
35. Han, JF, Jiang, T and Fan, XL et al. Recombination of human coxsackievirus B5 in hand, foot, and mouth disease patients, China. Emerg Infect Dis 2012; 18: 351-3.
36. Zhang, Y, Wang, D and Yan, D et al. Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol 2010; 48: 619-22.
37. Zong, W, He, Y and Yu, S et al. Molecular phylogeny of Coxsackievirus A16 in Shenzhen, China, from 2005 to 2009. J Clin Microbiol 2011; 49: 1659-61.
38. Tee, KK, Lam, TT and Chan, YF et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 2010; 84: 3339-50.
39. Deshpande, JM, Nadkami, SS and Francis, PP. Enterovirus 71 isolated from a case of acute flaccid paralysis in India represents a new genotype. Curr Sci 2003; 84: 1350-3.
40. Wu, WH, Kuo, TC and Lin, YT et al. Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012. PLoS One 2013; 8: e83711.
41. Li, L, He, Y and Yang, H et al. Genetic characteristics of human enterovirus 71 and coxsackievirus A16 circulating from 1999 to 2004 in Shenzhen, People's Republic of China. J Clin Microbiol 2005; 43: 3835-9.
42. Zhang, Y, Tan, XJ and Wang, HY et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009; 44: 262-7.
43. Du, J, Wang, X and Hu, Y et al. Changing aetiology of hand, foot and mouth disease in Linyi, China, 2009-2011. Clin Microbiol Infect 2013; 20: O47-9.
44. Yang, F, Du, J and Hu, Y et al. Enterovirus coinfection during an outbreak of hand, foot, and mouth disease in Shandong, China. Clin Infect Dis 2011; 53: 400-1.
45. Zhang, T, Du, J and Xue, Y et al. Epidemics and frequent recombination within species in outbreaks of human enterovirus B-associated hand, foot and mouth disease in Shandong China in 2010 and 2011. PLoS One 2013; 8: e67157.
46. Liu, X, Mao, N and Yu, Wet al. Genetic characterization of emerging coxsackievirus A12 associated with hand, foot and mouth disease in Qingdao, China. Arch Virol 2014; 159: 2497-502.
47. Tapparel, C, Siegrist, F and Petty, TJ et al. Picornavirus and enterovirus diversity with associated human diseases. Infect Genet Evol 2013; 14: 282-93.
48. Puenpa, J, Mauleekoonphairoj, J and Linsuwanon, P et al. Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012. PLoS One 2014; 9: e98888.
49. Osterback, R, Vuorinen, T and Linna, M et al. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg Infect Dis 2009; 15: 1485-8.
50. Lo, SH, Huang, YC and Huang, CG et al. Clinical and epidemiologic features of Coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009. J Microbiol Immunol Infect 2011; 44: 252-7.
51. Centers for Disease Control and Prevention (CDC). Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6-Alabama, Connecticut, California, and Nevada, November 2011-February 2012. MMWR Morb Mortal Wkly Rep 2012; 61: 213-4.
52. Flett, K, Youngster, I and Huang, J et al. Hand, foot, and mouth disease caused by coxsackievirus a6. Emerg Infect Dis 2012; 18: 1702-4.
53. Fujimoto, T, Iizuka, S and Enomoto, M et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011. Emerg Infect Dis 2012; 18: 337-9.
54. Lott, JP, Liu, K and Landry, ML et al. Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection. J Am Acad Dermatol 2013; 69: 736-41.
55. Montes, M, Artieda, J and Pineiro, LD et al. Hand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 2011. Emerg Infect Dis 2013; 19: 676-8.
56. Puenpa, J, Chieochansin, T and Linsuwanon, P et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg Infect Dis 2013; 19: 641-3.
57. Han, JF, Xu, S and Zhang, Y et al. Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013. J Infect 2014; 69: 303-5.
58. Hongyan, G, Chengjie, M and Qiaozhi, Y et al. Hand, foot and mouth disease caused by coxsackievirus A6, Beijing, 2013. Pediatr Infect Dis J 2014; 33: 1302-3.
59. Li, JL, Yuan, J and Yang, F et al. Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. J Infect 2014; 69: 299-303.
60. Sinclair, C, Gaunt, E and Simmonds, P et al. Atypical hand, foot, and mouth disease associated with coxsackievirus A6 infection, Edinburgh, United Kingdom, January to February 2014. Euro Surveill 2014; 19: 20745.
61. Yang, F, Yuan, J andWang, X et al. Severe hand, foot, and mouth disease and coxsackievirus A6-Shenzhen, China. Clin Infect Dis 2014; 59: 1504-5.
62. Stewart, CL, Chu, EY and Introcaso, CE et al. Coxsackievirus A6-induced handfoot-mouth disease. JAMA Dermatol 2013; 149: 1419-21.
63. Downing, C, Ramirez-Fort, MK and Doan, HQ et al. Coxsackievirus A6 associated hand, foot and mouth disease in adults: clinical presentation and review of the literature. J Clin Virol 2014; 60: 381-6.
64. Harris, PN, Wang, AD and Yin, Met al. Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults. Lancet Infect Dis 2014; 14: 1043.
65. He, YQ, Chen, L and Xu, WB et al. Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6-and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J Clin Microbiol 2013; 51: 3560-6.
66. Wong, KT, Munisamy, B and Ong, KC et al. The distribution of inflammation and virus in human enterovirus 71 encephalomyelitis suggests possible viral spread by neural pathways. J Neuropathol Exp Neurol 2008; 67: 162-9.
67. WHO. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). 2011.
68. Yang, Y, Wang, H and Gong, E et al. Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent epidemic in the People's Republic of China: a histopathologic, immunohistochemical, and reverse transcription polymerase chain reaction study. Hum Pathol 2009; 40: 1288-95.
69. Shieh, WJ, Jung, SM and Hsueh, C et al. Pathologic studies of fatal cases in outbreak of hand, foot, and mouth disease, Taiwan. Emerg Infect Dis 2001; 7: 146-8.
70. Chong, CY, Chan, KP and Shah, VA et al. Hand, foot and mouth disease in Singapore: a comparison of fatal and non-fatal cases. Acta Paediatr 2003; 92: 1163-9.
71. Lum, LC, Wong, KT and Lam, SK et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998; 133: 795-8.
72. Wang, SM, Lei, HY and Yu, CK et al. Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 2008; 198: 1002-6.
73. Zhang, Y, Liu, H and Wang, L et al. Comparative study of the cytokine/ chemokine response in children with differing disease severity in enterovirus 71-induced hand, foot, and mouth disease. PLoS One 2013; 8: e67430.
74. Chen, Z, Li, R and Xie, Z et al. IL-6, IL-10 and IL-13 are associated with pathogenesis in children with Enterovirus 71 infection. Int J Clin Exp Med 2014; 7: 2718-23.
75. Han, J, Wang, Y and Gan, X et al. Serum cytokine profiles of children with human enterovirus 71-associated hand, foot, and mouth disease. J Med Virol 2014; 86: 1377-85.
76. Tung, WH, Lee, IT and Hsieh, HL et al. EV71 induces COX-2 expression via c-Src/PDGFR/PI3K/Akt/p42/p44 MAPK/AP-1 and NF-kappaB in rat brain astrocytes. J Cell Physiol 2010; 224: 376-86.
77. Tung, WH, Sun, CC and Hsieh, HL et al. EV71 induces VCAM-1 expression via PDGF receptor, PI3-K/Akt, p38 MAPK JNK, NF-kappaB in vascular smooth muscle cells. Cell Signal 2007; 19: 2127-37.
78. Khong, WX, Foo, DG and Trasti, SL et al. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 2011; 85: 3067-76.
79. Zhang, Y, Cui, W and Liu, L et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 2011; 91: 1337-50.
80. Fujii, K, Nagata, N and Sato, Y et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA 2013; 110: 14753-8.
81. Nagata, N, Shimizu, H and Ami, Y et al. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 2002; 67: 207-16.
82. Chua, BH, Phuektes, P and Sanders, SA et al. The molecular basis of mouse adaptation by human enterovirus 71. J Gen Virol 2008; 89: 1622-32.
83. Caine, EA, Partidos, CD and Santangelo, JD et al. Adaptation of enterovirus 71 to adult interferon deficient mice. PLoS One 2013; 8: e59501.
84. Wang, YF and Yu, CK. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014; 21: 31.
85. Wang, W, Duo, J and Liu, J et al. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect 2011; 13: 862-70.
86. Yamayoshi, S, Yamashita, Y and Li, J et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009; 15: 798-801.
87. Nishimura, Y, Shimojima, M and Tano, Y et al. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. NatMed 2009; 15: 794-7.
88. Yang, SL, Chou, YT and Wu, CN et al. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol 2011; 85: 11809-20.
89. Lin, JY and Shih, SR. Cell and tissue tropism of enterovirus 71 and other enteroviruses infections. J Biomed Sci 2014; 21: 18.
90. Nishimura, Y and Shimizu, H. Cellular receptors for human enterovirus species a. Front Microbiol 2012; 3: 105.
91. Lin, HY, Yang, YT and Yu, SL et al. Caveolar endocytosis is required for human PSGL-1-mediated enterovirus 71 infection. J Virol 2013; 87: 9064-76.
92. Hussain, KM, Leong, KL and Ng, MM et al. The essential role of clathrinmediated endocytosis in the infectious entry of human enterovirus 71. J Biol Chem 2011; 286: 309-21.
93. Chen, CS, Yao, YC and Lin, SC et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol 2007; 81: 8996-9003.
94. Yamayoshi, S, Ohka, S and Fujii, K et al. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 2013; 87: 3335-47.
95. Lin, YW, Yu, SL and Shao, HY et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013; 8: e57591.
96. Liu, J, Dong, W and Quan, X et al. Transgenic expression of human P-selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. Arch Virol 2012; 157: 539-43.
97. Dobrikova, E, Florez, P and Bradrick, S et al. Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3' nontranslated region. Proc Natl Acad Sci USA 2003; 100: 15125-30.
98. Cordey, S, Petty, TJ and Schibler, M et al. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 2012; 8: e1002826.
99. Kok, CC, Phuektes, P and Bek, E et al. Modification of the untranslated regions of human enterovirus 71 impairs growth in a cell-specificmanner. J Virol 2012; 86: 542-52.
100. Yeh, MT, Wang, SW and Yu, CK et al. A single nucleotide in stem loop II of 5'-untranslated region contributes to virulence of enterovirus 71 in mice. PLoS One 2011; 6: e27082.
101. Yan, N and Chen, ZJ. Intrinsic antiviral immunity. Nat Immunol 2012; 13: 214-22.
102. Kuo, RL, Kao, LT and Lin, SJ et al. MDA5 plays a crucial role in enterovirus 71 RNA-mediated IRF3 activation. PLoS One 2013; 8: e63431.
103. Zhu, K, Yang, J and Luo, K et al. TLR3 signaling in macrophages is indispensable for the protective immunity of invariant natural killer T cells against enterovirus 71 infection. PLoS Pathog 2015; 11: e1004613.
104. Liu, ML, Lee, YP and Wang, YF et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 2005; 86: 3263-9.
105. Lei, X, Liu, X and Ma, Y et al. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. J Virol 2010; 84: 8051-61.
106. Feng, Q, Langereis, MA and Lork, M et al. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. J Virol 2014; 88: 3369-78.
107. Wang, B, Xi, X and Lei, X et al. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog 2013; 9: e1003231.
108. Mukherjee, A, Morosky, SA and Delorme-Axford, E et al. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog 2011; 7: e1001311.
109. Lei, X, Sun, Z and Liu, X et al. Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3. J Virol 2011; 85: 8811-8.
110. Lei, X, Xiao, X and Xue, Q et al. Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses. J Virol 2013; 87: 1690-8.
111. Lee, YP, Wang, YF and Wang, JR et al. Enterovirus 71 blocks selectively type I interferon production through the 3C viral protein in mice. J Med Virol 2012; 84: 1779-89.
112. Lei, X, Han, N and Xiao, X et al. Enterovirus 71 3C inhibits cytokine expression through cleavage of the TAK1/TAB1/TAB2/TAB3 complex. J Virol 2014; 88: 9830-41.
113. Zheng, Z, Li, H and Zhang, Z et al. Enterovirus 71 2C protein inhibits TNFalpha-mediated activation of NF-kappaB by suppressing IkappaB kinase beta phosphorylation. J Immunol 2011; 187: 2202-12.
114. Devasthanam, AS. Mechanisms underlying the inhibition of interferon signaling by viruses. Virulence 2014; 5: 270-7.
115. Lu, J, Yi, L and Zhao, J et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J Virol 2012; 86: 3767-76.
116. Hung, HC, Wang, HC and Shih, SR et al. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis 2011; 203: 1784-90.
117. Lin, JY, Li, ML and Huang, PN et al. Heterogeneous nuclear ribonuclear protein K interacts with the enterovirus 71 5' untranslated region and participates in virus replication. J Gen Virol 2008; 89: 2540-9.
118. Lin, JY, Li, ML and Shih, SR. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res 2009; 37: 47-59.
119. Lin, JY, Shih, SR and Pan, M et al. hnRNP A1 interacts with the 5' untranslated regions of enterovirus 71 and Sindbis virus RNA and is required for viral replication. J Virol 2009; 83: 6106-14.
120. Huang, PN, Lin, JY and Locker, N et al. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res 2011; 39: 9633-48.
121. Leong, SY, Ong, BK and Chu, JJ. The role of Misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71. PLoS Pathog 2015; 11: e1004686.
122. Weng, KF, Li, ML and Hung, CT et al. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog 2009; 5: e1000593.
123. Greninger, AL, Knudsen, GM and Betegon, M et al. The 3A protein from multiple picornaviruses utilizes the golgi adaptor protein ACBD3 to recruit PI4KIIIbeta. J Virol 2011; 86: 3605-16.
124. Arita, M, Kojima, H and Nagano, T et al. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol 2011; 85: 2364-72.
125. Roulin, PS, Lotzerich, Mand Torta, F et al. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface. Cell Host Microbe 2014; 16: 677-90.
126. Hsu, NY, Ilnytska, O and Belov, G et al. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 2010; 141: 799-811.
127. Tang, WF, Yang, SY and Wu, BW et al. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. J Biol Chem 2007; 282: 5888-98.
128. Shih, SR, Stollar, V and Lin, JY et al. Identification of genes involved in the host response to enterovirus 71 infection. J Neurovirol 2004; 10: 293-304.
129. Leong, WF and Chow, VT. Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection. Cell Microbiol 2006; 8: 565-80.
130. Kuo, RL, Lin, YH and Wang, RY et al. Proteomics analysis of EV71-infected cells reveals the involvement of host protein NEDD4L in EV71 replication. J Proteome Res 2015; 14: 1818-30.
131. Cui, L, Guo, X and Qi, Y et al. Identification of microRNAs involved in the host response to enterovirus 71 infection by a deep sequencing approach.JBiomed Biotechnol 2010; 2010: 425939.
132. Cui, L, Qi, Y and Li, H et al. Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-footand-mouth disease. PLoS One 2011; 6: e27071.
133. Wen, BP, Dai, HJ and Yang, YH et al. MicroRNA-23b inhibits enterovirus 71 replication through downregulation of EV71 VPl protein. Intervirology 2013; 56: 195-200.
134. Zheng, Z, Ke, X and Wang, M et al. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J Virol 2013; 87: 5645-56.
135. Ho, BC, Yu, IS and Lu, LF et al. Inhibition of miR-146a prevents enterovirusinduced death by restoring the production of type I interferon. Nat Commun 2014; 5: 3344.
136. Xu, C, He, X and Zheng, Z et al. Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response. J Virol 2014; 88: 11356-68.
137. Wang, X, Peng, W and Ren, J et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 2012; 19: 424-9.
138. Plevka, P, Perera, R and Cardosa, J et al. Crystal structure of human enterovirus 71. Science 2012; 336: 1274.
139. Plevka, P, Perera, R and Yap, ML et al. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci USA 2013; 110: 5463-7.
140. De Colibus, L, Wang, X and Spyrou, JA et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol 2014; 21: 282-8.
141. Tuthill, TJ, Groppelli, E and Hogle, JM et al. Picornaviruses. Curr TopMicrobiol Immunol 2010; 343: 43-89.
142. Rodriguez, PL and Carrasco, L. Poliovirus protein 2C contains two regions involved in RNA binding activity. J Biol Chem 1995; 270: 10105-12.
143. Banerjee, R, Echeverri, A and Dasgupta, A. Poliovirus-encoded 2C polypeptide specifically binds to the 3'-terminal sequences of viral negative-strand RNA. J Virol 1997; 71: 9570-8.
144. Vance, LM, Moscufo, N and Chow, M et al. Poliovirus 2C region functions during encapsidation of viral RNA. J Virol 1997; 71: 8759-65.
145. Novoa, I and Carrasco, L. Cleavage of eukaryotic translation initiation factor 4G by exogenously added hybrid proteins containing poliovirus 2Apro in HeLa cells: effects on gene expression.Mol Cell Biol 1999; 19: 2445-54.
146. Thompson, SR and Sarnow, P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology 2003; 315: 259-66.
147. Cui, S, Wang, J and Fan, T et al. Crystal structure of human enterovirus 71 3C protease. J Mol Biol 2011; 408: 449-61.
148. Mu, Z, Wang, B and Zhang, X et al. Crystal structure of 2A proteinase from hand, foot and mouth disease virus. J Mol Biol 2013; 425: 4530-43.
149. Lu, G, Qi, J and Chen, Z et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol 2011; 85: 10319-31.
150. Wang, J, Fan, T and Yao, X et al. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol 2011; 85: 10021-30.
151. Cai, Q, Yameen, M and Liu, W et al. Conformational plasticity of the 2A proteinase from enterovirus 71. J Virol 2013; 87: 7348-56.
152. Wang, Y, Yang, B and Zhai, Y et al. A peptidyl aldehyde NK-1.8k suppresses EV71 and EV68 infection by targeting at 3Cpro. Antimicrob Agents Chemother 2015; 59: 2636-46.
153. Wu, Y, Lou, Z and Miao, Y et al. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth disease pandemic in China. Protein Cell 2010; 1: 491-500.
154. Chen, C, Wang, Y and Shan, C et al. Crystal structure of enterovirus 71 RNAdependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation. J Virol 2013; 87: 5755-68.
155. Meng, T and Kwang, J. Attenuation of human enterovirus 71 high-replicationfidelity variants in AG129 mice. J Virol 2014; 88: 5803-15.
156. Chen, TC, Chang, HY and Lin, PF et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother 2009; 53: 2740-7.
157. Zinkernagel, RM, LaMarre, A and Ciurea, A et al. Neutralizing antiviral antibody responses. Adv Immunol 2001; 79: 1-53.
158. Ji, H, Li, L and Chen, XQ et al. Seroepidemiology of human enterovirus71 and coxsackievirusA16 in Jiangsu province, China. Virol J 2012; 9: 248.
159. Rabenau, HF, Richter, M and Doerr, HW et al. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 2010; 199: 45-50.
160. Zhu, FC, Liang, ZL and Meng, FY et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS One 2012; 7: e37206.
161. Zhu, FC, Meng, FY and Li, JX et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381: 2024-32.
162. Li, R, Liu, L and Mo, Z et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370: 829-37.
163. Zhu, F, Xu, W and Xia, J et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370: 818-28.
164. Shen, YW, Jing, XL and Zheng, LL et al. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis 2014; 210: 1073-82.
165. Mao, Q, Cheng, T and Zhu, F et al. The cross-neutralizing activity of enterovirus 71 subgenotype C4 vaccines in healthy Chinese infants and children. Plos One 2013; 8: e79599.
166. Mao, QY, Wang, YP and Liang, ZL et al. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and poliovirus immunizations in humans and animals. Hum Vaccin Immunother 2015. doi:10.1080/21645515.2015.1011975.
167. Cai, Y, Ku, Z and Liu, Q et al. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014; 32: 2406-12.
168. Wang, J, Qi, S and Zhang, X et al. Coxsackievirus A 16 infection does not interfere with the specific immune response induced by an enterovirus 71 inactivated vaccine in rhesus monkeys. Vaccine 2014; 32: 4436-42.
169. Yang, E, Cheng, C and Zhang, Y et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother 2014; 10: 1266-73.
170. Cai, Y, Liu, Q and Huang, X et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013; 31: 2215-21.
171. An, QW, Su, ZG and Pan, RW et al. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother 2014; 10: 628-39.
172. Sun, S, Jiang, L and Liang, Z et al. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccin Immunother 2014; 10: 2885-95.
173. Ku, Z, Liu, Q and Ye, X et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014; 32: 4296-303.
174. Chen, HF, Chang, MH and Chiang, BL et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 2006; 24: 2944-51.
175. Wu, TC, Wang, YF and Lee, YP et al. Immunity to a virulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007; 81: 10310-5.
176. Chen, HL, Huang, JY and Chu, TW et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 2008; 26: 2882-9.
177. Premanand, B, Prabakaran, M and Kiener, TK et al. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS One 2013; 8: e55536.
178. Zhang, F, Hao, C and Zhang, S et al. Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge. Virol J 2014; 11: 80.
179. Raha, AR, Varma, NR and Yusoff, K et al. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Appl Microbiol Biotechnol 2005; 68: 75-81.
180. Arita, M, Shimizu, H and Nagata, N et al. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 2005; 86: 1391-401.
181. Kung, YH, Huang, SW and Kuo, PH et al. Introduction of a strong temperaturesensitive phenotype into enterovirus 71 by altering an amino acid of virus 3D polymerase. Virology 2010; 396: 1-9.
182. Arita, M, Ami, Y and Wakita, T et al. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 2008; 82: 1787-97.
183. Miao, LY, Pierce, C and Gray-Johnson, J et al. Monoclonal antibodies to VP1 recognize a broad range of enteroviruses. J Clin Microbiol 2009; 47: 3108-13.
184. Liu, CC, Chou, AH and Lien, SP et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011; 29: 4362-72.
185. Kirk, K, Poh, CL and Fecondo, J et al. Cross-reactive neutralizing antibody epitopes against Enterovirus 71 identified by an in silico approach. Vaccine 2012; 30: 7105-10.
186. Zhao, M, Bai, Y and Liu, W et al. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol 2013; 13: 287.
187. Kiener, TK, Jia, Q and Meng, T et al. A novel universal neutralizingmonoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein. PLoS Negl Trop Dis 2014; 8: e2895.
188. Xu, L, He, D and Li, Z et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly crossneutralizing epitope within the VP2 EF loop. Theranostics 2014; 4: 498-513.
189. Ye, X, Ku, Z and Liu, Q et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 2014; 88: 72-81.